The Transitioning Children to Optimal Regimens of Paediatric Dolutegravir (TORPEDO) Study
This slide deck walks through the initial results of the Transitioning Children to Optimal Regimens of Paediatric Dolutegravir (TORPEDO)...
top of page
A framework to support new product introduction in national health systems
Resource Library
- Mar 17, 2022
Adult DRV/r (400/50mg) Clinical Action Memo
Darunavir (DRV) is a best-in-class protease inhibitor (PI) used in combination with other antiretroviral (ARV) drugs for the...
131
- Oct 11, 2021
Pediatric DTG Implementation Memo (English, French)
CHAI has developed this memo to lay out information for national HIV programs considering the introduction of pediatric...
66
- Dec 4, 2018
ICAP Considerations for the Introduction of TLD in National Programs
This document is intended to support country programs to develop clinical guidance and implementation plans for the introduction of the...
19
- Aug 1, 2018
TLD Resources
CHAI's TLD resources help countries in creating the best plan for TLD introduction. CHAI TLD Clinical Action Memo CHAI DTG Use In Women...
34
- Jun 1, 2017
CHAI Stakeholder Mapping for Treatment Optimization
This tool is helpful for identifying the key stakeholders involved in new product introduction. This tool encourages users to think...
3
- May 9, 2017
CHAI New Product Rollout Planning Template
The CHAI New Product Rollout Planning Template is designed to provide a skeleton for Ministries of Health and implementing partners to...
4
bottom of page